Evaluate clinically significant response and treatment outcomes

The manuals converge on the need to judge treatment change against meaningful clinical thresholds, not just note that scores or experiences have shifted. Across the extracts, this includes interpreting remission and response criteria in rapid-acting depression trials, tracking symptom change over repeated sessions, and observing whether shifts in PTSD, pain, depression, or existential distress are accompanied by broader functional or wellbeing gains. They also overlap in treating outcome evaluation as longitudinal and context-sensitive. Several sources emphasise comparing change from baseline over time, distinguishing short-term improvement from sustained benefit, and weighing symptom change alongside other information such as acute experience measures, safety data, quality of life, spiritual well-being, or participant-reported functioning. The LSD source adds a stronger explicit focus on balancing benefit against harm, including adverse effects and psychiatric deterioration. The manuals differ in how tightly they define clinical significance and what outcomes they prioritise. The GH001 trial gives specific numerical thresholds for remission and response, while the psilocybin cancer follow-up refers more broadly to clinically significant criteria and wider psychosocial outcomes. The MDMA trial centres PTSD symptom severity and functional impairment, the ketamine pilot focuses on pain and mental health across sessions, and the LSD source is more explicitly concerned with both benefit and risk across the treatment course, including whether to continue treatment.